Wyeth News

Wyeth News From AOL News

FDA Panel Rejects Experimental Weight Loss Pill

GAITHERSBURG, MD. (July 15) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight. The Food and Drug Administration panel voted 10-6 against Vivus's Qnexa, citing...

Positive Qnexa Review Follows 5 Notable Diet Pill Disasters

(July 13) -- Qnexa, one of three anti-obesity drugs being reviewed by the Food and Drug Administration, effectively reduces body weight among obese patients. That's the bottom line from the FDA today, ahead of a final decision in October. But the agency remains wary of Qnexa's potential side effects: The drug has been...

Wyeth News From the Web

06/01/12 BioAlliance Pharma: Combined Shareholders Meeting Source: PharmiWeb.com BioAlliance Pharma SA (Paris:BIO), a Company dedicated to orphan oncology products and specialty products, announces that its Shareholders' meeting was held today at its headquarters and has adopted all the resolutions supported by its Board of Directors.
05/31/12 BioAlliance Pharma: Combined Shareholders Meeting Source: Infospace Inc BioAlliance Pharma SA (Paris:BIO), a Company dedicated to orphan oncology products and specialty products, announces that its Shareholders' meeting was held today at its headquarters and has adopted all the resolutions supported by its Board of Directors.
05/31/12 Temptime Announces Business Expansion in Asia Source: Andhra News Temptime Corporation , the world leader in time temperature indicators, announced the opening of a business office in Beijing, China, marking a significant advancement in their global effort to improve distribution of temperature-sensitive pharmaceutical products in and around the Asian region.
05/30/12 Oral, Injected Methotrexate Have Similar Efficacy in... Source: Health Day Oral and injected methotrexate are equally effective for treating children with juvenile idiopathic arthritis, according to a study published online May 30 in Arthritis Care & Research.
05/30/12 Almirall Source: Pharmalicensing.com Almirall, a fully integrated pharmaceutical Pan-European company, is actively looking for late stage opportunities in the areas of Respiratory, Gastrointestinal, Dermatology, Neurology and Pain. In Respiratory and Dermatology, Almirall also considers earlier stages of development.